Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emilio Bria

Showing results (161-170 of 377) with videos related to

Pageof 38
Sort By:
Cancers|July 8, 2020
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era?Ina Valeria Zurlo, Michele Basso, Antonia Strippoli, et al.
Breast (Edinburgh, Scotland)|February 4, 2026
Predicting progression-free survival in hormone-receptor positive (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approachSergio Pannunzio, Luca Mastrantoni, Noemi Maliziola, et al.
Clinical Genitourinary Cancer|January 18, 2018
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate CancerRoberto Iacovelli, Chiara Ciccarese, Emilio Bria, et al.
Translational Lung Cancer Research|August 25, 2021
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be doneLorenzo Belluomini, Alessandra Dodi, Alberto Caldart, et al.
Cancers|May 25, 2024
Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative ReviewFilippo Lococo, Galal Ghaly, Marco Chiappetta, et al.
Plos One|June 19, 2015
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary CancersLuisa Carbognin, Sara Pilotto, Michele Milella, et al.
La Radiologia Medica|May 6, 2021
Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)Anna Merlotti, Alessio Bruni, Paolo Borghetti, et al.
Future Oncology (London, England)|January 10, 2015
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Sebastiano Buti, Chiara Ciccarese, Daniele Zanoni, et al.
Critical Reviews in Oncology/Hematology|September 8, 2014
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysisEmilio Bria, Francesco Massari, Francesca Maines, et al.
Histology and Histopathology|March 8, 2014
Adenocarcinoma of the paraurethral glands: a case reportFrancesco Massari, Chiara Ciccarese, Alessandra Modena, et al.
Pageof 38

Showing results (161-170 of 377) with videos related to

Sort By:
Pageof 38
Cancers|July 8, 2020
Treatment of Locally Advanced Gastric Cancer (LAGC): Back to Lauren's Classification in Pan-Cancer Analysis Era?Ina Valeria Zurlo, Michele Basso, Antonia Strippoli, et al.
Breast (Edinburgh, Scotland)|February 4, 2026
Predicting progression-free survival in hormone-receptor positive (HR+/HER2-) metastatic breast cancer (MBC) treated with CDK4/6 inhibitors: A machine learning approachSergio Pannunzio, Luca Mastrantoni, Noemi Maliziola, et al.
Clinical Genitourinary Cancer|January 18, 2018
The Cardiovascular Toxicity of Abiraterone and Enzalutamide in Prostate CancerRoberto Iacovelli, Chiara Ciccarese, Emilio Bria, et al.
Translational Lung Cancer Research|August 25, 2021
A narrative review on tumor microenvironment in oligometastatic and oligoprogressive non-small cell lung cancer: a lot remains to be doneLorenzo Belluomini, Alessandra Dodi, Alberto Caldart, et al.
Cancers|May 25, 2024
Implementation of Artificial Intelligence in Personalized Prognostic Assessment of Lung Cancer: A Narrative ReviewFilippo Lococo, Galal Ghaly, Marco Chiappetta, et al.
Plos One|June 19, 2015
Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary CancersLuisa Carbognin, Sara Pilotto, Michele Milella, et al.
La Radiologia Medica|May 6, 2021
Sequential chemo-hypofractionated RT versus concurrent standard CRT for locally advanced NSCLC: GRADE recommendation by the Italian Association of Radiotherapy and Clinical Oncology (AIRO)Anna Merlotti, Alessio Bruni, Paolo Borghetti, et al.
Future Oncology (London, England)|January 10, 2015
Prognostic and predictive factors in patients treated with chemotherapy for advanced urothelial cancer: where do we stand?Sebastiano Buti, Chiara Ciccarese, Daniele Zanoni, et al.
Critical Reviews in Oncology/Hematology|September 8, 2014
Progression-free survival as primary endpoint in randomized clinical trials of targeted agents for advanced renal cell carcinoma. Correlation with overall survival, benchmarking and power analysisEmilio Bria, Francesco Massari, Francesca Maines, et al.
Histology and Histopathology|March 8, 2014
Adenocarcinoma of the paraurethral glands: a case reportFrancesco Massari, Chiara Ciccarese, Alessandra Modena, et al.
Pageof 38